Chromocell Therapeutics Corp

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

PTHS$8.90-5.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

	Preferred A Shares	Preferred A Shares Par	Preferred C Shares	Preferred C Shares Par	Common Shares	Par	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders’ Deficit
Balance, December 31, 2022	600,000	$60	—	$—	$1,111,112	$111	$4,432,148	$(6,138,856)	$(3,706,537)
Stock-based compensation	—	—	—	—	—	—	272,221	—	272,221
Net loss	—	—	—	—	—	—	—	(966,561)	(966,561)
Balance, March 31, 2023	600,000	$60	—	$—	$1,111,112	$111	$2,704,369	$(7,105,417)	$(4,440,877)
Stock option compensation	—	—	—	—	—	—	327,338	—	327,338
Issuance cost from shares issued on extension of bridge loan	—	—	—	—	5,556	1	125,999	—	126,000
Shares forfeited	—	—	—	—	(133,745)	(13)	13	—	—
Net loss	—	—	—	—	—	—	—	—	(953,347)
Balance June 30, 2023	600,000	$60	—	$—	$982,923	99	$3,157,719	$(8,058,764)	$(4,900,886)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

	Preferred A Shares	Preferred A Shares Par	Preferred C Shares	Preferred C Shares Par	Common Shares	Par	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders’ Deficit
Balance, December 31, 2023	600,000	$60	—	$—	$3,906,300	$391	$7,074,646	$(13,519,649)	$(6,444,552)
Stock-based compensation	—	—	—	—	—	—	292,552	—	292,552
Issuance cost from common stock issued for extension of bridge loan	—	—	—	—	81,112	9	447,770	—	447,779
Conversion of preferred stock	(600,000)	(60)	—	—	499,429	50	10	—	—
Common stock issued for cash	—	—	—	—	1,100,000	110	5,971,890	—	5,972,000
Standby agreement	—	—	—	—	37,500	4	(4)	—	—
Recission of common stock	—	—	—	—	(111,129)	(11)	(91,501)	—	(91,512)
Transfer of liabilities to Chromocell Corp. for preferred C shares	—	—	2,600	—	—	—	2,153,362	—	2,153,363
Common stock issued for conversion of notes	—	—	—	—	253,492	25	1,362,796	—	1,362,821
Net loss	—	—	—	—	—	—	—	(2,562,300)	(2,562,330)
Balance March 31, 2024	—	$—	2,600	$—	$5,766,704	$578	$17,211,521	$(16,081,979)	$1,130,120
Stock option compensation	—	—	—	—	—	—	366,503	—	366,503
RSU expense	—	—	—	—	—	—	13,975	—	13,975
Shares issued for services	—	—	—	—	56,462	6	78,494	—	78,500
Net loss	—	—	—	—	—	—	—	(1,771,619)	(1,771,619)
Balance June 30, 2024	—	$—	2,600	$—	$5,823,166	$584	$17,670,493	$(17,853,598)	$(182,521)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.